24/7 Market News Snapshot 22 May, 2025 – Imunon, Inc. Common Stock (NASDAQ:IMNN)

May 22, 2025

DENVER, Colo., 22 May, 2025 (www.247marketnews.com) – (NASDAQ:IMNN) are discussed in this article.
IMUNON, Inc. (IMNN), a clinical-stage biotechnology company, has shown promising market activity, opening at $0.42 with a significant increase of 11.72%, indicating heightened investor interest. Currently trading at $0.446, the stock reflects positive market sentiment, supported by a trading volume of 19.14 million shares. This robust activity often points to impending price movements, with key resistance levels identified around $0.45 and support near $0.40. Investors are advised to monitor sustained volume and potential price consolidation above these thresholds, as IMNN positions itself for potential growth.

In a related development, IMUNON has announced the withdrawal of its public offering request filed with the Securities and Exchange Commission (SEC) on April 4, 2025. This proactive decision, preceding the effectiveness of the Registration Statement and ensuring no securities were sold, underscores IMUNON’s focus on advancing its core mission of developing innovative immunotherapies aimed at harnessing the immune system to tackle various diseases.

Central to IMUNON’s initiatives is the DNA-mediated immunotherapy, IMNN-001, which targets localized treatment for advanced ovarian cancer. Following successful completion of a Phase 2 clinical trial (OVATION 2), this therapy demonstrates the potential to activate immune responses directly at tumor sites. Furthermore, IMUNON’s R&D efforts are progressing with the development of IMNN-101, a COVID-19 booster vaccine that has shown promising results in initial human studies.

With a portfolio that includes versatile delivery methods like TheraPlas® and PlaCCine®, IMUNON is dedicated to advancing plasmid DNA technology and generating effective healthcare solutions. The company remains committed to exploring partnerships that align with its vision of delivering transformative therapies, emphasizing its significant role within the biotechnology sector.

Related news for (IMNN)

NASDAQ and NYSE quotes and data are delayed 15 minutes unless indicated otherwise. Market data and exchange information are provided for informational purposes only and is not intended for trading purposes. Neither 24/7 Market News Editors, 247 Market News, or data and content providers shall be liable for any errors or omissions, delays, misquotes or other market information relayed in any press materials. You should Use Realtime data to conduct due diligence before investing or trading, and trading in any stock is risky you could lose all your money.